Robles BioCeutics patents stem cell skincare breakthrough with GlowSelle™

Robles BioCeutics has taken a major step in protecting its cutting-edge skincare technology. The company recently filed a PCT patent application for its GlowSelle™ platform, a stem cell-derived system designed to rejuvenate skin. Legal support came from Knobbe Martens, a top U.S. intellectual property firm specialising in biotech innovations. The patent covers Robles BioCeutics' Injury Mimetic™ method, which replicates injury signals in lab-grown stem cells. This process boosts the production of growth factors, exosomes, and other regenerative compounds. According to the application, the technique enhances angiogenic, regenerative, and anti-inflammatory effects compared to conventional stem cell treatments.

GlowSelle™ aims to stimulate collagen, reduce inflammation, and restore skin vitality. The platform claims to deliver a broader range of bioactive molecules than traditional stem cell products. However, no clinical trials have yet confirmed its efficacy in humans. While some components, like GHK-Cu, have limited clinical data, others—such as BPC-157 and TB-500—remain untested in people.

Jason Jardine, a partner at Knobbe Martens, led the patent filing. The firm structured the application to safeguard both the scientific method and the mechanistic basis of GlowSelle™. Robles BioCeutics, a regenerative dermatology company, focuses on senolytic and stem cell research to develop science-backed skincare solutions. The patent filing secures Robles BioCeutics' intellectual property for its Injury Mimetic™ and GlowSelle™ technologies. The company continues to push forward with research, though human trials have not yet validated the platform's claims. For now, the innovation remains protected as the firm pursues further development in regenerative skincare.